A cell therapy developer will pursue licensing partnerships at a major biotech convention and present its allogeneic mesenchymal stem cell program to pharma executives.
Key Takeaways
- Company representatives will meet global pharma executives to explore licensing partnerships
- Laromestrocel targets HLHS, Alzheimer’s, pediatric dilated cardiomyopathy, and aging-related frailty
- Phase 2b ELPIS II enrollment finished and top-line HLHS data are expected August 2026